Kawashima O, Kurihara T, Kamiyoshihara M, Sakata S, Ishikawa S, Morishita Y
Department of Surgery, National Sanatorium Nishigunma Hospital, Shibukawa, Gunma, Japan.
Am J Clin Oncol. 1999 Aug;22(4):396-8. doi: 10.1097/00000421-199908000-00015.
To determine the efficacy of aclarubicin hydrochloride in local control of malignant pericardial effusion, the authors carried out a trial of pericardial drainage with local administration of this agent in five patients, whose effusions had produced cardiac tamponade. All patients were women, and their primary cancers, all initially treated surgically, had arisen in the breast (two patients), or lung (three patients). Mean patient age was 54.2 years (range, 43-62). In four patients, improvement permitted removal of the drainage catheter. Two patients (40%) had a complete remission of the malignant pericardial effusion. The other three patients were difficult to evaluate because nonpericardial metastases limited their survival. All patients, however, showed disappearance of malignant cells from the pericardial sac with no cytopathologically demonstrable recurrence. In our few patients, intrapericardial aclarubicin appeared to be highly effective against malignant pericardial effusion.
为确定盐酸阿柔比星在局部控制恶性心包积液方面的疗效，作者对5例因积液导致心脏压塞的患者进行了心包引流并局部应用该药物的试验。所有患者均为女性，其原发性癌症最初均接受手术治疗，分别来自乳腺（2例）或肺（3例）。患者平均年龄为54.2岁（范围43 - 62岁）。4例患者病情改善后得以拔除引流导管。2例患者（40%）恶性心包积液完全缓解。另外3例患者因非心包转移限制了生存而难以评估。然而，所有患者心包腔内恶性细胞均消失，且无细胞病理学可证实的复发。在我们这少数患者中，心包内注射阿柔比星似乎对恶性心包积液非常有效。
